CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: TMEM170A (ImmuneEditome ID:124491)

1. Gene summary of enriched editing regions for TMEM170A

check button Gene summary
Gene informationGene symbol

TMEM170A

Gene ID

124491

GeneSynonymsTMEM170
GeneCytomap

16q23.1

GeneTypeprotein-coding
GeneDescriptiontransmembrane protein 170A|transmembrane protein 170
GeneModificationdate20230329
UniprotIDB3KT46;Q8WVE7;H3BRD7;H3BQT8;H3BS26
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr16:75443874-75446172:-ENST00000568559.1ENSG00000166822.11TMEM170AsplicingAluSx1,AluY,MER57A1,AluJb,(T)n,AluSg4,(TA)nchr16:75443874-75446172:-.alignment


Top

2. Tumor-specific enriched editing regions for TMEM170A


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr16:75443874-75446172:-BRCAEER3.5470e-10image
ENSG00000166822.11,TMEM170ABRCAEAG7.7520e-10image
chr16:75443874-75446172:-COADEER1.9027e-10image
ENSG00000166822.11,TMEM170ACOADEAG7.5823e-11image
chr16:75443874-75446172:-KIRPEER2.0082e-02image
ENSG00000166822.11,TMEM170AKIRPEAG1.9544e-02image
chr16:75443874-75446172:-PRADEER4.8870e-02image
ENSG00000166822.11,TMEM170APRADEAG4.8034e-02image
chr16:75443874-75446172:-THCAEER3.3868e-14image
ENSG00000166822.11,TMEM170ATHCAEAG1.9250e-14image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000166822.11,TMEM170AUCSCliEAG5.7404e-032.5829e-02-0.3479image
chr16:75443874-75446172:-UCSCliEER5.7404e-032.5829e-02-0.3479image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for TMEM170A


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr16:75443874-75446172:-GBMEERENSG00000108179,PPIF0.25073.1209e-026.0690e-080.4076imageNCNBP;CSTF2T;DDX54;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPC;IGF2BP1;IGF2BP2;MOV10;NOP56;PRPF8;RBFOX2;RBM10;SF3B4;TRA2A;TROVE2;U2AF2PPIFMast_cells_restingGSVA_HALLMARK_ANGIOGENESIS
chr16:75443874-75446172:-UCECEERENSG00000171603,CLSTN10.33791.3787e-024.2099e-070.4235imageNACIN1;CNBP;CSTF2T;DDX54;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPC;IGF2BP1;IGF2BP2;KHDRBS2;MOV10;NOP56;PRPF8;RBFOX2;RBM10;SF3B4;TRA2A;TROVE2;U2AF2CLSTN1GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS
chr16:75443874-75446172:-PCPGEERENSG00000072736,NFATC30.44487.0500e-053.3452e-080.4628imageNACIN1;CNBP;CSTF2T;DDX54;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPC;IGF2BP1;IGF2BP2;KHDRBS2;MOV10;NOP56;PRPF8;RBFOX2;RBM10;SF3B4;TRA2A;TROVE2;U2AF2NFATC3Mast_cells_activatedGSVA_HALLMARK_MITOTIC_SPINDLE
chr16:75443874-75446172:-PCPGEERENSG00000269427,CTC-429P9.10.44341.0239e-041.2383e-070.4453imageNELAVL1;FUSNAT_cells_CD4_memory_restingGSVA_HALLMARK_MITOTIC_SPINDLE
chr16:75443874-75446172:-PCPGEERENSG00000101350,KIF3B0.41983.0360e-041.6496e-060.4074imageNACIN1;CNBP;CSTF2T;DDX54;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPC;IGF2BP1;IGF2BP2;KHDRBS2;MOV10;NOP56;PRPF8;RBFOX2;RBM10;SF3B4;TRA2A;TROVE2;U2AF2NADendritic_cells_restingGSVA_HALLMARK_MITOTIC_SPINDLE
chr16:75443874-75446172:-PCPGEERENSG00000152683,SLC30A60.41593.6259e-049.8262e-070.4154imageNACIN1;CNBP;CSTF2T;DDX54;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPC;IGF2BP1;IGF2BP2;KHDRBS2;MOV10;NOP56;PRPF8;RBFOX2;RBM10;SF3B4;TRA2A;TROVE2;U2AF2NANeutrophilsGSVA_HALLMARK_PROTEIN_SECRETION
chr16:75443874-75446172:-PCPGEERENSG00000171865,RNASEH10.41563.6548e-042.1959e-060.4030imageNACIN1;CNBP;CSTF2T;DDX54;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPC;IGF2BP1;IGF2BP2;KHDRBS2;MOV10;NOP56;PRPF8;RBFOX2;RBM10;SF3B4;TRA2A;TROVE2;U2AF2NADendritic_cells_restingGSVA_HALLMARK_MITOTIC_SPINDLE
chr16:75443874-75446172:-PCPGEERENSG00000198690,FAN10.41613.6864e-041.1702e-060.4127imageNACIN1;CNBP;CSTF2T;DDX54;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPC;IGF2BP1;IGF2BP2;KHDRBS2;MOV10;NOP56;PRPF8;RBFOX2;RBM10;SF3B4;TRA2A;TROVE2;U2AF2FAN1Mast_cells_activatedGSVA_HALLMARK_MITOTIC_SPINDLE
chr16:75443874-75446172:-PCPGEERENSG00000135392,DNAJC140.40765.2306e-043.0742e-070.4325imageNACIN1;CNBP;CSTF2T;DDX54;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPC;IGF2BP1;IGF2BP2;KHDRBS2;MOV10;NOP56;PRPF8;RBFOX2;RBM10;SF3B4;TRA2A;TROVE2;U2AF2NAPlasma_cellsGSVA_HALLMARK_MITOTIC_SPINDLE
chr16:75443874-75446172:-PCPGEERENSG00000138095,LRPPRC0.40196.7430e-041.5705e-060.4082imageNACIN1;CNBP;CSTF2T;DDX54;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPC;IGF2BP1;IGF2BP2;KHDRBS2;MOV10;NOP56;PRPF8;RBFOX2;RBM10;SF3B4;TRA2A;TROVE2;U2AF2NAPlasma_cellsGSVA_HALLMARK_MITOTIC_SPINDLE

More results



Top

4. Enriched editing regions and immune related splicing for TMEM170A


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000166822.11,TMEM170A
COADEAGESENSG00000138641.11chr488667455:88667488:88667891:88668081:88669859:88670023-0.16192.3891e-029.7598e-20-0.5933imageNADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM47;RC3H1;RNF219;SAFB2;SF3B4;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDF1;ZNF184NANK_cells_activatedGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
ENSG00000166822.11,TMEM170A
ESCAEAGIRENSG00000099330.4chr1917226614:17226869:17226999:17227199-0.22432.2801e-023.0369e-10-0.4958imageNADAR;AUH;BCCIP;BUD13;CNBP;CSTF2T;DDX3X;DDX54;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LARP4B;LIN28;LIN28B;LSM11;MOV10;NONO;NOP56;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;YWHAGNAMacrophages_M0GSVA_HALLMARK_UV_RESPONSE_DN
chr16:75443874-75446172:-
ESCAEERIRENSG00000065243.14chr188828480:88828623:88829009:88829167-0.23271.8058e-021.4393e-09-0.5270imageNACIN1;CNBP;CSTF2T;DDX54;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPC;IGF2BP1;IGF2BP2;KHDRBS2;MOV10;NOP56;PRPF8;RBFOX2;RBM10;SF3B4;TRA2A;TROVE2;U2AF2PKN2GSVA_HALLMARK_P53_PATHWAY
chr16:75443874-75446172:-
ESCAEERIRENSG00000099330.4chr1917226614:17226869:17226999:17227199-0.22152.2278e-023.3168e-10-0.4949imageNCNBP;CSTF2T;DDX54;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPC;IGF2BP1;IGF2BP2;MOV10;NOP56;PRPF8;RBFOX2;SF3B4;TRA2A;TROVE2;U2AF2NAMacrophages_M0GSVA_HALLMARK_UV_RESPONSE_DN
ENSG00000166822.11,TMEM170A
ESCAEAGIRENSG00000065243.14chr188828480:88828623:88829009:88829167-0.23382.0298e-021.4462e-09-0.5270imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RC3H1;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZFP36;ZNF184PKN2GSVA_HALLMARK_P53_PATHWAY
chr16:75443874-75446172:-
PCPGEERMEXENSG00000118816.5chr477055322:77055380:77055961:77056100:77058506:77058635:77066248:77066405-0.35692.2336e-022.2035e-06-0.4029imageNACIN1;CNBP;CSTF2T;DDX54;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPC;IGF2BP1;IGF2BP2;KHDRBS2;MOV10;NOP56;PRPF8;RBFOX2;RBM10;SF3B4;TRA2A;TROVE2;U2AF2NAGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000166822.11,TMEM170A
PCPGEAGMEXENSG00000135446.12chr1257748590:57748617:57749181:57749317:57751206:57751736:57752174:57752276-0.36491.5790e-022.2469e-06-0.4026imageNADAR;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM27;RC3H1;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZFP36;ZNF184CDK4NeutrophilsGSVA_HALLMARK_MITOTIC_SPINDLE
chr16:75443874-75446172:-
PCPGEERMEXENSG00000135446.12chr1257748590:57748617:57749181:57749317:57751206:57751736:57752174:57752276-0.36971.4345e-022.0223e-06-0.4043imageNACIN1;CNBP;CSTF2T;DDX54;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPC;IGF2BP1;IGF2BP2;KHDRBS2;MOV10;NOP56;PRPF8;RBFOX2;RBM10;SF3B4;TRA2A;TROVE2;U2AF2CDK4NeutrophilsGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000166822.11,TMEM170A
PCPGEAGIRENSG00000083812.7chr1958469179:58469306:58469727:58469844-0.31943.0134e-021.9810e-06-0.4184imageNAIFM1;AUH;BUD13;CNBP;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TNRC6A;TRA2A;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;YWHAG;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_MITOTIC_SPINDLE
chr16:75443874-75446172:-
PCPGEERMEXENSG00000244754.4chr1332517487:32518003:32521372:32521449:32527407:32537027:32538617:32538684-0.38099.1366e-031.9100e-07-0.4393imageNACIN1;CNBP;CSTF2T;DDX54;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPC;IGF2BP1;IGF2BP2;KHDRBS2;MOV10;NOP56;PRPF8;RBFOX2;RBM10;SF3B4;TRA2A;TROVE2;U2AF2NAT_cells_CD4_memory_restingGSVA_HALLMARK_MITOTIC_SPINDLE

More results



Top

5. Enriched editing regions and immune infiltration for TMEM170A


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr16:75443874-75446172:-ACCEERDendritic_cells_activated8.9399e-040.4317image
ENSG00000166822.11,TMEM170AACCEAGDendritic_cells_activated8.9399e-040.4317image
chr16:75443874-75446172:-BLCAEERT_cells_follicular_helper3.7033e-040.2013image
ENSG00000166822.11,TMEM170ABLCAEAGT_cells_follicular_helper3.3982e-040.2025image
chr16:75443874-75446172:-BRCAEERT_cells_CD4_memory_resting3.0508e-030.0946image
ENSG00000166822.11,TMEM170ABRCAEAGT_cells_CD4_memory_resting1.7677e-030.0996image
chr16:75443874-75446172:-CESCEERDendritic_cells_activated3.7769e-02-0.1284image
ENSG00000166822.11,TMEM170ACESCEAGDendritic_cells_activated3.6527e-02-0.1290image
chr16:75443874-75446172:-COADEERMast_cells_activated8.1881e-03-0.1624image
ENSG00000166822.11,TMEM170ACOADEAGT_cells_regulatory_(Tregs)1.5492e-02-0.1486image
chr16:75443874-75446172:-DLBCEERPlasma_cells3.1464e-020.3935image
ENSG00000166822.11,TMEM170ADLBCEAGPlasma_cells3.1464e-020.3935image
chr16:75443874-75446172:-ESCAEERT_cells_regulatory_(Tregs)4.0332e-03-0.2261image
ENSG00000166822.11,TMEM170AESCAEAGT_cells_regulatory_(Tregs)4.0644e-03-0.2260image
chr16:75443874-75446172:-GBMEERMacrophages_M01.9816e-03-0.2398image
ENSG00000166822.11,TMEM170AGBMEAGMacrophages_M02.0932e-03-0.2386image
chr16:75443874-75446172:-HNSCEERMacrophages_M11.8160e-020.1193image
ENSG00000166822.11,TMEM170AHNSCEAGMacrophages_M11.7953e-020.1195image
chr16:75443874-75446172:-KICHEERMacrophages_M26.0714e-03-0.3394image
ENSG00000166822.11,TMEM170AKICHEAGMacrophages_M26.0714e-03-0.3394image
chr16:75443874-75446172:-KIRCEERMonocytes2.0349e-02-0.1222image
ENSG00000166822.11,TMEM170AKIRCEAGMonocytes1.8559e-02-0.1240image
chr16:75443874-75446172:-KIRPEERNeutrophils3.8503e-020.1340image
ENSG00000166822.11,TMEM170AKIRPEAGNeutrophils3.8904e-020.1337image
ENSG00000166822.11,TMEM170ALAMLEAGMacrophages_M23.8227e-030.2364image
chr16:75443874-75446172:-LGGEERMacrophages_M12.3224e-040.1608image
ENSG00000166822.11,TMEM170ALGGEAGMacrophages_M12.3224e-040.1608image
chr16:75443874-75446172:-LIHCEERT_cells_CD4_memory_activated3.4461e-02-0.1404image
ENSG00000166822.11,TMEM170ALIHCEAGMonocytes4.2596e-020.1344image
chr16:75443874-75446172:-MESOEERNK_cells_resting1.4488e-030.3928image
ENSG00000166822.11,TMEM170AMESOEAGNK_cells_resting1.4488e-030.3928image
chr16:75443874-75446172:-OVEERT_cells_CD4_memory_activated3.2155e-030.1764image
ENSG00000166822.11,TMEM170AOVEAGT_cells_gamma_delta2.4636e-030.1809image
chr16:75443874-75446172:-PCPGEERT_cells_CD4_memory_resting1.9486e-030.2703image
ENSG00000166822.11,TMEM170APCPGEAGT_cells_CD4_memory_resting1.9810e-030.2699image
chr16:75443874-75446172:-PRADEERNK_cells_activated1.9186e-020.1155image
ENSG00000166822.11,TMEM170APRADEAGNK_cells_activated1.7596e-020.1170image
chr16:75443874-75446172:-SARCEERT_cells_follicular_helper4.4249e-020.1634image
ENSG00000166822.11,TMEM170ASARCEAGT_cells_follicular_helper4.4249e-020.1634image
chr16:75443874-75446172:-SKCMEERMast_cells_resting2.4159e-02-0.1191image
ENSG00000166822.11,TMEM170ASKCMEAGT_cells_CD4_memory_activated2.5111e-020.1182image
chr16:75443874-75446172:-STADEERNK_cells_activated2.0578e-040.1926image
ENSG00000166822.11,TMEM170ASTADEAGNK_cells_activated5.6579e-040.1791image
chr16:75443874-75446172:-TGCTEERNeutrophils2.2128e-02-0.1899image
ENSG00000166822.11,TMEM170ATGCTEAGNeutrophils2.2362e-02-0.1896image
chr16:75443874-75446172:-THYMEERT_cells_gamma_delta3.8223e-04-0.3971image
ENSG00000166822.11,TMEM170ATHYMEAGT_cells_gamma_delta5.8177e-04-0.3832image
chr16:75443874-75446172:-UCECEERMacrophages_M01.0738e-020.2214image
ENSG00000166822.11,TMEM170AUCECEAGMacrophages_M01.0833e-020.2203image


Top

6. Enriched editing regions and immune gene sets for TMEM170A


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr16:75443874-75446172:-ACCGSVA_HALLMARK_SPERMATOGENESISEER2.2650e-030.3998image
ENSG00000166822.11,TMEM170AACCGSVA_HALLMARK_SPERMATOGENESISEAG2.2650e-030.3998image
ENSG00000166822.11,TMEM170ABLCAGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.8663e-030.1763image
chr16:75443874-75446172:-BLCAGSVA_HALLMARK_MITOTIC_SPINDLEEER2.0216e-030.1750image
chr16:75443874-75446172:-BRCAGSVA_HALLMARK_MITOTIC_SPINDLEEER5.7891e-040.1098image
ENSG00000166822.11,TMEM170ABRCAGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.6605e-040.1134image
ENSG00000166822.11,TMEM170ACESCGSVA_HALLMARK_GLYCOLYSISEAG8.8535e-03-0.1611image
chr16:75443874-75446172:-CESCGSVA_HALLMARK_GLYCOLYSISEER6.7405e-03-0.1670image
ENSG00000166822.11,TMEM170ACHOLGSVA_HALLMARK_UV_RESPONSE_UPEAG1.5286e-02-0.4538image
chr16:75443874-75446172:-CHOLGSVA_HALLMARK_UV_RESPONSE_UPEER1.5286e-02-0.4538image
ENSG00000166822.11,TMEM170ACOADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG7.6437e-03-0.1635image
chr16:75443874-75446172:-COADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.6261e-020.1290image
chr16:75443874-75446172:-DLBCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.1574e-02-0.4548image
ENSG00000166822.11,TMEM170ADLBCGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.1574e-02-0.4548image
chr16:75443874-75446172:-ESCAGSVA_HALLMARK_MITOTIC_SPINDLEEER5.7797e-03-0.2173image
ENSG00000166822.11,TMEM170AESCAGSVA_HALLMARK_MITOTIC_SPINDLEEAG7.4526e-03-0.2108image
chr16:75443874-75446172:-GBMGSVA_HALLMARK_FATTY_ACID_METABOLISMEER5.7459e-040.2660image
ENSG00000166822.11,TMEM170AGBMGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG5.2012e-040.2680image
chr16:75443874-75446172:-HNSCGSVA_HALLMARK_MYC_TARGETS_V2EER1.4222e-03-0.1606image
ENSG00000166822.11,TMEM170AHNSCGSVA_HALLMARK_MYC_TARGETS_V2EAG1.4865e-03-0.1600image
chr16:75443874-75446172:-KICHGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER2.4885e-030.3718image
ENSG00000166822.11,TMEM170AKICHGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG2.4885e-030.3718image
ENSG00000166822.11,TMEM170ALAMLGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.0714e-020.2092image
chr16:75443874-75446172:-LGGGSVA_HALLMARK_MITOTIC_SPINDLEEER6.1707e-08-0.2347image
ENSG00000166822.11,TMEM170ALGGGSVA_HALLMARK_MITOTIC_SPINDLEEAG6.1707e-08-0.2347image
chr16:75443874-75446172:-LIHCGSVA_HALLMARK_UV_RESPONSE_DNEER1.7565e-090.3860image
ENSG00000166822.11,TMEM170ALIHCGSVA_HALLMARK_UV_RESPONSE_DNEAG3.5164e-090.3785image
ENSG00000166822.11,TMEM170ALUADGSVA_HALLMARK_IL2_STAT5_SIGNALINGEAG2.5458e-040.1685image
chr16:75443874-75446172:-LUADGSVA_HALLMARK_IL2_STAT5_SIGNALINGEER3.9472e-040.1635image
ENSG00000166822.11,TMEM170AOVGSVA_HALLMARK_COAGULATIONEAG2.1659e-030.1832image
chr16:75443874-75446172:-OVGSVA_HALLMARK_COAGULATIONEER3.8902e-030.1729image
chr16:75443874-75446172:-PCPGGSVA_HALLMARK_MITOTIC_SPINDLEEER1.6586e-040.3257image
ENSG00000166822.11,TMEM170APCPGGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.7514e-040.3246image
ENSG00000166822.11,TMEM170APRADGSVA_HALLMARK_DNA_REPAIREAG1.5486e-020.1194image
chr16:75443874-75446172:-PRADGSVA_HALLMARK_DNA_REPAIREER1.4768e-020.1202image
ENSG00000166822.11,TMEM170ASARCGSVA_HALLMARK_GLYCOLYSISEAG4.3918e-03-0.2298image
chr16:75443874-75446172:-SARCGSVA_HALLMARK_GLYCOLYSISEER4.3918e-03-0.2298image
ENSG00000166822.11,TMEM170ASKCMGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.5209e-020.1280image
chr16:75443874-75446172:-SKCMGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER1.4322e-020.1294image
chr16:75443874-75446172:-STADGSVA_HALLMARK_UV_RESPONSE_DNEER4.2431e-04-0.1830image
ENSG00000166822.11,TMEM170ASTADGSVA_HALLMARK_UV_RESPONSE_DNEAG3.5957e-04-0.1853image
chr16:75443874-75446172:-TGCTGSVA_HALLMARK_PROTEIN_SECRETIONEER1.8294e-020.1958image
ENSG00000166822.11,TMEM170ATGCTGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.0080e-020.1929image
chr16:75443874-75446172:-THCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.1375e-030.1496image
ENSG00000166822.11,TMEM170ATHCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.4565e-030.1463image
ENSG00000166822.11,TMEM170ATHYMGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG1.0821e-030.3655image
chr16:75443874-75446172:-THYMGSVA_HALLMARK_PANCREAS_BETA_CELLSEER8.5471e-05-0.4352image
ENSG00000166822.11,TMEM170AUCECGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG1.5498e-030.2718image
chr16:75443874-75446172:-UCECGSVA_HALLMARK_TGF_BETA_SIGNALINGEER9.0575e-040.2855image
ENSG00000166822.11,TMEM170AUCSGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.1249e-020.3369image
chr16:75443874-75446172:-UCSGSVA_HALLMARK_MITOTIC_SPINDLEEER3.1249e-020.3369image


Top

7. Enriched editing regions and drugs for TMEM170A


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000166822.11,TMEM170AACCAS601245EAG2.0975e-020.3079image
chr16:75443874-75446172:-ACCAS601245EER2.0975e-020.3079image
ENSG00000166822.11,TMEM170ABLCABMS.536924EAG3.8653e-040.2007image
chr16:75443874-75446172:-BLCABMS.536924EER2.9752e-040.2044image
chr16:75443874-75446172:-BRCADMOGEER1.4225e-04-0.1213image
ENSG00000166822.11,TMEM170ABRCADMOGEAG6.0525e-05-0.1276image
chr16:75443874-75446172:-CESCEHT.1864EER2.6331e-03-0.1851image
ENSG00000166822.11,TMEM170ACESCEHT.1864EAG2.7559e-03-0.1839image
ENSG00000166822.11,TMEM170ACHOLBAY.61.3606EAG2.0622e-02-0.4352image
chr16:75443874-75446172:-CHOLBAY.61.3606EER2.0622e-02-0.4352image
chr16:75443874-75446172:-COADBleomycinEER4.8938e-03-0.1727image
ENSG00000166822.11,TMEM170ACOADGefitinibEAG1.4180e-04-0.2316image
chr16:75443874-75446172:-DLBCBAY.61.3606EER6.8068e-03-0.4834image
ENSG00000166822.11,TMEM170ADLBCBAY.61.3606EAG6.8068e-03-0.4834image
ENSG00000166822.11,TMEM170AESCACGP.60474EAG3.2755e-03-0.2311image
chr16:75443874-75446172:-ESCACGP.60474EER1.8896e-03-0.2438image
ENSG00000166822.11,TMEM170AGBMBosutinibEAG5.1471e-040.2683image
chr16:75443874-75446172:-GBMBosutinibEER4.7275e-040.2700image
ENSG00000166822.11,TMEM170AHNSCCytarabineEAG5.2734e-040.1743image
chr16:75443874-75446172:-HNSCCytarabineEER5.0224e-040.1750image
chr16:75443874-75446172:-KICHImatinibEER7.8282e-060.5266image
ENSG00000166822.11,TMEM170AKICHImatinibEAG7.8282e-060.5266image
chr16:75443874-75446172:-KIRCCisplatinEER2.2550e-03-0.1605image
ENSG00000166822.11,TMEM170AKIRCCisplatinEAG2.9976e-03-0.1560image
ENSG00000166822.11,TMEM170AKIRPAS601245EAG2.1938e-030.1972image
chr16:75443874-75446172:-KIRPAS601245EER2.0985e-030.1980image
ENSG00000166822.11,TMEM170ALAMLCCT018159EAG1.4296e-020.2010image
chr16:75443874-75446172:-LGGAxitinibEER9.2637e-080.2316image
ENSG00000166822.11,TMEM170ALGGAxitinibEAG9.2637e-080.2316image
chr16:75443874-75446172:-LIHCBMS.536924EER9.4107e-070.3187image
ENSG00000166822.11,TMEM170ALIHCBMS.536924EAG5.0105e-070.3255image
chr16:75443874-75446172:-LUADKU.55933EER3.5926e-04-0.1646image
ENSG00000166822.11,TMEM170ALUADKU.55933EAG3.4881e-04-0.1648image
chr16:75443874-75446172:-LUSCCGP.082996EER5.3551e-03-0.1349image
ENSG00000166822.11,TMEM170ALUSCCGP.082996EAG5.5867e-03-0.1342image
ENSG00000166822.11,TMEM170AMESOAICAREAG3.8150e-02-0.2619image
chr16:75443874-75446172:-MESOAICAREER3.8150e-02-0.2619image
chr16:75443874-75446172:-OVDasatinibEER1.3558e-02-0.1484image
ENSG00000166822.11,TMEM170AOVDasatinibEAG1.8663e-02-0.1413image
chr16:75443874-75446172:-PAADCyclopamineEER2.3523e-020.1843image
ENSG00000166822.11,TMEM170APAADCyclopamineEAG2.3834e-020.1839image
ENSG00000166822.11,TMEM170APCPGAZD6244EAG1.0052e-030.2863image
chr16:75443874-75446172:-PCPGAZD6244EER9.9053e-040.2866image
chr16:75443874-75446172:-PRADBIBW2992EER6.4865e-030.1341image
ENSG00000166822.11,TMEM170APRADBIBW2992EAG6.2440e-030.1347image
chr16:75443874-75446172:-READBX.795EER2.4262e-02-0.2348image
ENSG00000166822.11,TMEM170AREADBX.795EAG2.4262e-02-0.2348image
ENSG00000166822.11,TMEM170ASARCErlotinibEAG4.5059e-030.2292image
chr16:75443874-75446172:-SARCErlotinibEER4.5059e-030.2292image
ENSG00000166822.11,TMEM170ASKCMMG.132EAG2.2225e-02-0.1210image
chr16:75443874-75446172:-SKCMMG.132EER2.0938e-02-0.1223image
chr16:75443874-75446172:-STADABT.263EER1.0248e-020.1342image
ENSG00000166822.11,TMEM170ASTADABT.263EAG1.1446e-020.1322image
chr16:75443874-75446172:-THCAAICAREER3.6647e-06-0.2117image
ENSG00000166822.11,TMEM170ATHCAAICAREAG2.1732e-06-0.2162image
ENSG00000166822.11,TMEM170ATHYMBX.795EAG1.5406e-04-0.4182image
chr16:75443874-75446172:-THYMBX.795EER2.3422e-05-0.4648image
ENSG00000166822.11,TMEM170AUCECAKT.inhibitor.VIIIEAG7.4808e-04-0.2888image
chr16:75443874-75446172:-UCECAKT.inhibitor.VIIIEER7.6481e-04-0.2894image
chr16:75443874-75446172:-UCSElesclomolEER1.1441e-020.3912image
ENSG00000166822.11,TMEM170AUCSElesclomolEAG1.1441e-020.3912image
ENSG00000166822.11,TMEM170AUVMDMOGEAG4.0128e-02-0.3768image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType